Benign lymph node enlargement can mislead surgeons into overstaging colorectal cancer (CRC), causing unnecessarily extended lymphadenectomy. This study aimed to develop and validate a machine learning (ML) classifier utilizing multi-phase CT (MPCT) radiomics for accurate evaluation of the pre-treatment status of enlarged tumor-draining lymph nodes (TDLNs; defined as long-axis diameter ≥ 10 mm). This study included 430 pathologically confirmed CRC patients who underwent radical resection, stratified into a development cohort (n = 319; January 2015-December 2019, retrospectively enrolled) and test cohort (n = 111; January 2020-May 2023, prospectively enrolled). Radiomics features were extracted from multi-regional lesions (tumor and enlarged TDLNs) on MPCT. Following rigorous feature selection, optimal features were employed to train multiple ML classifiers. The top-performing classifier based on area under receiver operating characteristic curves (AUROCs) was validated. Ultimately, 15 classifiers based on features from multi-regional lesions were constructed (Tumor_{N, A}, _V; Ln_N, _A, _V; Ln, lymph node; _N, non-contrast phase; _A, arterial phase; _V, venous phase). Among all classifiers, the enlarged TDLNs fusion MPCT classifier (Ln_NAV) demonstrated the highest predictive efficacy, with AUROCs and AUPRCs of 0.820 and 0.883, respectively. When pre-treatment clinical variables were integrated (Clinical_Ln_NAV), the model's efficacy improved, with AUROCs of 0.839, AUPRCs of 0.903, accuracy of 76.6%, sensitivity of 67.7%, and specificity of 89.1%. The classifier Clinical_Ln_NAV demonstrated well performance in evaluating pre-treatment status of enlarged TDLNs. This tool may support clinicians in developing individualized treatment plans for CRC patients, helping to avoid inappropriate treatment. Question There are currently no effective non-invasive tools to assess the status of enlarged tumor-draining lymph nodes in colorectal cancer prior to treatment. Findings Pre-treatment multi-phase CT radiomics, combined with clinical variables, effectively assessed the status of enlarged tumor-draining lymph nodes, achieving a specificity of 89.1%. Clinical relevance statement The multi-phase CT-based classifier may assist clinicians in developing individualized treatment plans for colorectal cancer patients, potentially helping to avoid inappropriate preoperative adjuvant therapy and unnecessary extended lymphadenectomy.

Renal cell carcinoma (RCC) represents the most prevalent malignant neoplasm of the kidney, with a rising global incidence. Tumor nuclear grade is a crucial prognostic factor, guiding treatment decisions, but current histopathological grading via biopsy is invasive and prone to sampling errors. This study aims to assess the diagnostic performance and quality of CT-based radiomics for preoperatively predicting RCC nuclear grade. A comprehensive search was conducted across PubMed, Scopus, Embase, and Web of Science to identify relevant studies up until 19 April 2025. Quality was assessed using the QUADAS-2 and METRICS tools. A bivariate random-effects meta-analysis was performed to evaluate model performance, including sensitivity, specificity, and Area Under the Curve (AUC). Results from separate validation cohorts were pooled, and clinical and combined models were analyzed separately in distinct analyses. A total of 26 studies comprising 1993 individuals in 10 external and 16 internal validation cohorts were included. Meta-analysis of radiomics models showed pooled AUC of 0.88, sensitivity of 0.78, and specificity of 0.82. Clinical and combined (clinical-radiomics) models showed AUCs of 0.73 and 0.86, respectively. QUADAS-2 revealed significant risk of bias in the Index Test and Flow and Timing domains. METRICS scores ranged from 49.7 to 88.4%, with an average of 66.65%, indicating overall good quality, though gaps in some aspects of study methodologies were identified. This study suggests that radiomics models show great potential and diagnostic accuracy for non-invasive preoperative nuclear grading of RCC. However, challenges related to generalizability and clinical applicability remain, as further research with standardized methodologies, external validation, and larger cohorts is needed to enhance their reliability and integration into routine clinical practice.

<b>Background:</b> Studies of artificial intelligence (AI) for lung nodule detection on CT have primarily been conducted in investigational settings and/or focused on lung cancer screening. <b>Objective:</b> To evaluate the impact of AI assistance on radiologists' diagnostic performance for detecting lung metastases on chest CT in patients with colorectal cancer (CRC) in real-world clinical practice and to assess the clinical utility of AI assistance in this setting. <b>Methods:</b> This retrospective study included patients with CRC who underwent chest CT as surveillance for lung metastasis from May 2020 to December 2020 (conventional interpretation) or May 2022 to December 2022 (AI-assisted interpretation). Between periods, the institution implemented a commercial AI lung nodule detection system. During the second period, radiologists interpreted examinations concurrently with AI-generated reports, using clinical judgment regarding whether to report AI-detected nodules. The reference standard for metastasis incorporated pathologic and clinical follow-up criteria. Diagnostic performance (sensitivity, specificity, accuracy), and clinical utility (diagnostic yield, false-referral rate, management changes after positive reports) were compared between groups based on clinical radiology reports. Net benefit was estimated using decision curve analysis equation. Standalone AI interpretation was evaluated. <b>Results:</b> The conventional interpretation group included 647 patients (mean age, 64±11 years; 394 men, 253 women; metastasis prevalence, 4.3%); AI-assisted interpretation group included 663 patients (mean age, 63±12 years; 381 men, 282 women; metastasis prevalence, 4.4%). The AI-assisted interpretation group compared with the conventional interpretation group showed higher sensitivity (72.4% vs 32.1%; p=.008), accuracy (98.5% vs 96.0%; p=.005), and frequency of management changes (55.2% vs 25.0%, p=.02), without significant difference in specificity (99.7% vs 98.9%; p=.11), diagnostic yield (3.2% vs 1.4%, p=.30) or false-referral rate (0.3% vs 1.1%, p=.10). AI-assisted interpretation had positive estimated net benefit across outcome ratios. Standalone AI correctly detected metastasis in 24 of 29 patients but had 381 false-positive detections in 634 patients without metastasis; only one AI false-positive was reported as positive by interpretating radiologists. <b>Conclusion:</b> AI assistance yielded increased sensitivity, accuracy, and frequency of management changes, without significantly changed specificity. False-positive AI results minimally impacted radiologists' interpretations. <b>Clinical Impact:</b> The findings support clinical utility of AI assistance for CRC metastasis surveillance.

BackgroundHepatic steatosis (HS) is a common cardiometabolic risk factor frequently present but under- diagnosed in patients with suspected or known coronary artery disease. We used artificial intelligence (AI) to automatically quantify hepatic tissue measures for identifying HS from CT attenuation correction (CTAC) scans during myocardial perfusion imaging (MPI) and evaluate their added prognostic value for all-cause mortality prediction. MethodsThis study included 27039 consecutive patients [57% male] with MPI scans from nine sites. We used an AI model to segment liver and spleen on low dose CTAC scans and quantify the liver measures, and the difference of liver minus spleen (LmS) measures. HS was defined as mean liver attenuation < 40 Hounsfield units (HU) or LmS attenuation < -10 HU. Additionally, we used seven sites to develop an AI liver risk index (LIRI) for comprehensive hepatic assessment by integrating the hepatic measures and two external sites to validate its improved prognostic value and generalizability for all-cause mortality prediction over HS. FindingsMedian (interquartile range [IQR]) age was 67 [58, 75] years and body mass index (BMI) was 29.5 [25.5, 34.7] kg/m2, with diabetes in 8950 (33%) patients. The algorithm identified HS in 6579 (24%) patients. During median [IQR] follow-up of 3.58 [1.86, 5.15] years, 4836 (18%) patients died. HS was associated with increased mortality risk overall (adjusted hazard ratio (HR): 1.14 [1.05, 1.24], p=0.0016) and in subpopulations. LIRI provided higher prognostic value than HS after adjustments overall (adjusted HR 1.5 [1.32, 1.69], p<0.0001 vs HR 1.16 [1.02, 1.31], p=0.0204) and in subpopulations. InterpretationsAI-based hepatic measures automatically identify HS from CTAC scans in patients undergoing MPI without additional radiation dose or physician interaction. Integrated liver assessment combining multiple hepatic imaging measures improved risk stratification for all-cause mortality. FundingNational Heart, Lung, and Blood Institute/National Institutes of Health. Research in context Evidence before this studyExisting studies show that fully automated hepatic quantification analysis from chest computed tomography (CT) scans is feasible. While hepatic measures show significant potential for improving risk stratification and patient management, CT attenuation correction (CTAC) scans from patients undergoing myocardial perfusion imaging (MPI) have rarely been utilized for concurrent and automated volumetric hepatic analysis beyond its current utilization for attenuation correction and coronary artery calcium burden assessment. We conducted a literature review on PubMed and Google Scholar on April 1st, 2025, using the following keywords: ("liver" OR "hepatic") AND ("quantification" OR "measure") AND ("risk stratification" OR "survival analysis" OR "prognosis" OR "prognostic prediction") AND ("CT" OR "computed tomography"). Previous studies have established approaches for the identification of hepatic steatosis (HS) and its prognostic value in various small- scale cohorts using either invasive biopsy or non-invasive imaging approaches. However, CT-based non- invasive imaging, existing research predominantly focuses on manual region-of-interest (ROI)-based hepatic quantification from selected CT slices or on identifying hepatic steatosis without comprehensive prognostic assessment in large-scale and multi-site cohorts, which hinders the association evaluation of hepatic steatosis for risk stratification in clinical routine with less precise estimates, weak statistical reliability, and limited subgroup analysis to assess bias effects. No existing studies investigated the prognostic value of hepatic steatosis measured in consecutive patients undergoing MPI. These patients usually present with multiple cardiovascular risk factors such as hypertension, dyslipidemia, diabetes and family history of coronary disease. Whether hepatic measures could provide added prognostic value over existing cardiometabolic factors is unknown. Furthermore, despite the diverse hepatic measures on CT in existing literature, integrated AI-based assessment has not been investigated before though it may improve the risk stratification further over HS. Lastly, previous research relied on dedicated CT scans performed for screening purposes. CTAC scans obtained routinely with MPI had never been utilized for automated HS detection and prognostic evaluation, despite being readily available at no additional cost or radiation exposure. Added value of this studyIn this multi-center (nine sites) international (three countries) study of 27039 consecutive patients undergoing myocardial perfusion imaging (MPI) with PET or SPECT, we used an innovative artificial intelligence (AI)- based approach for automatically segmenting the entire liver and spleen volumes from low-dose ungated CT attenuation correction (CTAC) scans acquired during MPI, followed by the identification of hepatic steatosis. We evaluated the added prognostic value of several key hepatic metrics--liver measures (mean attenuation, coefficient of variation (CoV), entropy, and standard deviation), and similar measures for the difference of liver minus spleen (LmS)--derived from volumetric quantification of CTAC scans with adjustment for existing clinical and MPI variables. A HS imaging criterion (HSIC: a patient has moderate or severe hepatic steatosis if the mean liver attenuation is < 40 Hounsfield unit (HU) or the difference of liver mean attenuation and spleen mean attenuation is < -10 HU) was used to detect HS. These hepatic metrics were assessed for their ability to predict all-cause mortality in a large-scale and multi-center patient cohort. Additionally, we developed and validated an eXtreme Gradient Boosting decision tree model for integrated liver assessment and risk stratification by combining the hepatic metrics with the demographic variables to derive a liver risk index (LIRI). Our results demonstrated strong associations between the hepatic metrics and all-cause mortality, even after adjustment for clinical variables, myocardial perfusion, and atherosclerosis biomarkers. Our results revealed significant differences in the association of HS with mortality in different sex, age, and race subpopulations. Similar differences were also observed in various chronic disease subpopulations such as obese and diabetic subpopulations. These results highlighted the modifying effects of various patient characteristics, partially accounting for the inconsistent association observed in existing studies. Compared with individual hepatic measures, LIRI showed significant improvement compared to HSIC-based HS in mortality prediction in external testing. All these demonstrate the feasibility of HS detection and integrated liver assessment from cardiac low-dose CT scans from MPI, which is also expected to apply for generic chest CT scans which have coverage of liver and spleen while prior studies used dedicated abdominal CT scans for such purposes. Implications of all the available evidenceRoutine point-of-care analysis of hepatic quantification can be seamlessly integrated into all MPI using CTAC scans to noninvasively identify HS at no additional cost or radiation exposure. The automatically derived hepatic metrics enhance risk stratification by providing additional prognostic value beyond existing clinical and imaging factors, and the LIRI enables comprehensive assessment of liver and further improves risk stratification and patient management.

We introduce a novel framework for learning vector representations of tree-structured geometric data focusing on 3D vascular networks. Our approach employs two sequentially trained Transformer-based autoencoders. In the first stage, the Vessel Autoencoder captures continuous geometric details of individual vessel segments by learning embeddings from sampled points along each curve. In the second stage, the Vessel Tree Autoencoder encodes the topology of the vascular network as a single vector representation, leveraging the segment-level embeddings from the first model. A recursive decoding process ensures that the reconstructed topology is a valid tree structure. Compared to 3D convolutional models, this proposed approach substantially lowers GPU memory requirements, facilitating large-scale training. Experimental results on a 2D synthetic tree dataset and a 3D coronary artery dataset demonstrate superior reconstruction fidelity, accurate topology preservation, and realistic interpolations in latent space. Our scalable framework, named VeTTA, offers precise, flexible, and topologically consistent modeling of anatomical tree structures in medical imaging.

To develop a machine learning-based workflow for patient-specific breast radiation dosimetry in CT. Two hundred eighty-six chest CT examinations, with corresponding right and left breast contours, were retrospectively collected from the radiotherapy department at our institution to develop and validate breast segmentation U-Nets. Additionally, Monte Carlo simulations were performed for each CT scan to determine radiation doses to the breasts. The derived breast doses, along with predictors such as X-ray tube current and radiomic features, were then used to train deep neural networks (DNNs) for breast dose prediction. The breast segmentation models achieved a mean dice similarity coefficient of 0.92, with precision and sensitivity scores above 0.90 for both breasts, indicating high segmentation accuracy. The DNNs demonstrated close alignment with ground truth values, with mean predicted doses of 5.05 ± 0.50 mGy for the right breast and 5.06 ± 0.55 mGy for the left breast, compared to ground truth values of 5.03 ± 0.57 mGy and 5.02 ± 0.61 mGy, respectively. The mean absolute percentage errors were 4.01 % (range: 3.90 %-4.12 %) for the right breast and 4.82 % (range: 4.56 %-5.11 %) for the left breast. The mean inference time was 30.2 ± 4.3 s. Statistical analysis showed no significant differences between predicted and actual doses (p ≥ 0.07). This study presents an automated, machine learning-based workflow for breast radiation dosimetry in CT, integrating segmentation and dose prediction models. The models and code are available at: https://github.com/eltzanis/ML-based-Breast-Radiation-Dosimetry-in-CT.

Fully automated, artificial intelligence (AI) -based software has recently become available for scalable body composition analysis. Prior to broad application in the clinical arena, validation studies are needed. Our goal was to compare the results of a fully automated, AI-based software with a semi-automatic software in a sample of hospitalized patients. A diverse group of patients with Coronovirus-2 (COVID-19) and evaluable computed tomography (CT) images were included in this retrospective cohort. Our goal was to compare multiple aspects of body composition procuring results from fully automated and semi-automated body composition software. Bland-Altman analyses and correlation coefficients were used to calculate average bias and trend of bias for skeletal muscle (SM), visceral adipose tissue (VAT), subcutaneous adipose tissue (SAT), intermuscular adipose tissue (IMAT), and total adipose tissue (TAT-the sum of SAT, VAT, and IMAT). A total of 141 patients (average (standard deviation (SD)) age of 58.2 (18.9), 61% male, and 31% White Non-Hispanic, 31% Black Non-Hispanic, and 33% Hispanic) contributed to the analysis. Average bias (mean ± SD) was small (in comparison to the SD) and negative for SM (-3.79 cm² ± 7.56 cm²) and SAT (-7.06 cm² ± 19.77 cm²), and small and positive for VAT (2.29 cm² ± 15.54 cm²). A large negative bias was observed for IMAT (-7.77 cm² ± 5.09 cm²), where fully automated software underestimated intramuscular tissue quantity relative to the semi-automated software. The discrepancy in IMAT calculation was not uniform across its range given a correlation coefficient of -0.625; as average IMAT increased, the bias (underestimation by fully automated software) was greater. When compared to a semi-automated software, a fully automated, AI-based software provides consistent findings for key CT body composition measures (SM, SAT, VAT, TAT). While our findings support good overall agreement as evidenced by small biases and limited outliers, additional studies are needed in other clinical populations to further support validity and advanced precision, especially in the context of body composition and malnutrition assessment.

Small cell lung cancer (SCLC) is aggressive with poor survival outcomes, and most patients develop resistance to chemotherapy. No predictive biomarkers currently guide therapy. This study evaluates radiomic features to predict PFS and OS in limited-stage SCLC (LS-SCLC) and assesses PFS, OS, and the added benefit of chemoimmunotherapy (CHIO) in extensive-stage SCLC (ES-SCLC). A total of 660 SCLC patients (470 ES-SCLC, 190 LS-SCLC) from three sites were analyzed. LS-SCLC patients received chemotherapy and radiation, while ES-SCLC patients received either chemotherapy alone or chemoimmunotherapy. Radiomic and quantitative vasculature tortuosity features were extracted from CT scans. A LASSO-Cox regression model was used to construct the ES- Risk-Score (ESRS) and LS- Risk-Score (LSRS). ESRS was associated with PFS in training (HR = 1.54, adj. P = .0013) and validation sets (HR = 1.32, adj. P = .0001; HR = 2.4, adj. P = .0073) and with OS in training (HR = 1.37, adj. P = .0054) and validation sets (HR = 1.35, adj. P < .0006; HR = 1.6, adj. P < .0085) in ES-SCLC patients treated with chemotherapy. High-risk patients had improved PFS (HR = 0.68, adj. P < .001) and OS (HR = 0.78, adj. P = .026) with chemoimmunotherapy. LSRS was associated with PFS in training and validation sets (HR = 1.9, adj. P = .007; HR = 1.4, adj. P = .0098; HR = 2.1, adj. P = .028) in LS-SCLC patients receiving chemoradiation. Radiomics is prognostic for PFS and OS and predicts chemoimmunotherapy benefit in high-risk ES-SCLC patients.

To develop and validate a deep learning model based on three-dimensional features (DL_3D) for distinguishing lung adenocarcinoma (LUAD) from tuberculoma (TBM). A total of 1160 patients were collected from three hospitals. A vision transformer network-based DL_3D model was trained, and its performance in differentiating LUAD from TBM was evaluated using validation and external test sets. The performance of the DL_3D model was compared with that of two-dimensional features (DL_2D), radiomics, and six radiologists. Diagnostic performance was assessed using the area under the receiver operating characteristic curves (AUCs) analysis. The study included 840 patients in the training set (mean age, 54.8 years [range, 19-86 years]; 514 men), 210 patients in the validation set (mean age, 54.3 years [range, 18-86 years]; 128 men), and 110 patients in the external test set (mean age, 54.7 years [range, 22-88 years]; 51 men). In both the validation and external test sets, DL_3D exhibited excellent diagnostic performance (AUCs, 0.895 and 0.913, respectively). In the test set, the DL_3D model showed better performance (AUC, 0.913; 95% CI: 0.854, 0.973) than the DL_2D (AUC, 0.804, 95% CI: 0.722, 0.886; p < 0.001), radiomics (AUC, 0.676, 95% CI: 0.574, 0.777; p < 0.001), and six radiologists (AUCs, 0.692 to 0.810; p value range < 0.001-0.035). The DL_3D model outperforms expert radiologists in distinguishing LUAD from TBM. Question Can a deep learning model perform in differentiating LUAD from TBM on non-enhanced CT images? Findings The DL_3D model demonstrated higher diagnostic performance than the DL_2D model, radiomics model, and six radiologists in differentiating LUAD and TBM. Clinical relevance The DL_3D model could accurately differentiate between LUAD and TBM, which can help clinicians make personalized treatment plans.

Automated 3D CT diagnosis empowers clinicians to make timely, evidence-based decisions by enhancing diagnostic accuracy and workflow efficiency. While multimodal large language models (MLLMs) exhibit promising performance in visual-language understanding, existing methods mainly focus on 2D medical images, which fundamentally limits their ability to capture complex 3D anatomical structures. This limitation often leads to misinterpretation of subtle pathologies and causes diagnostic hallucinations. In this paper, we present Hybrid Spatial Encoding Network (HSENet), a framework that exploits enriched 3D medical visual cues by effective visual perception and projection for accurate and robust vision-language understanding. Specifically, HSENet employs dual-3D vision encoders to perceive both global volumetric contexts and fine-grained anatomical details, which are pre-trained by dual-stage alignment with diagnostic reports. Furthermore, we propose Spatial Packer, an efficient multimodal projector that condenses high-resolution 3D spatial regions into a compact set of informative visual tokens via centroid-based compression. By assigning spatial packers with dual-3D vision encoders, HSENet can seamlessly perceive and transfer hybrid visual representations to LLM's semantic space, facilitating accurate diagnostic text generation. Experimental results demonstrate that our method achieves state-of-the-art performance in 3D language-visual retrieval (39.85% of R@100, +5.96% gain), 3D medical report generation (24.01% of BLEU-4, +8.01% gain), and 3D visual question answering (73.60% of Major Class Accuracy, +1.99% gain), confirming its effectiveness. Our code is available at https://github.com/YanzhaoShi/HSENet.